MannKind (NASDAQ:MNKD) said the U.S. Food and Drug Administration has approved Afrezza for pediatric patients with diabetes ...

On Friday, the FDA expanded its approved use of Afrezza — making it the first ever needle-free insulin option for pediatric ...

On Friday, the FDA expanded its approved use for kids 6 years and older who have Type 1 diabetes or those who require insulin ...

The FDA has approved the inhaled human insulin Afrezza (MannKind) for children aged 6 years or older with type 1 diabetes (T1D) or type 2 diabetes (T2D).

Enables dosing at the start of a meal, offering flexibility for children and adolescents as they manage school, sports, meals, and snacks ...

The FDA approved an inhaled needle-free insulin and a Delaware County teenager was part of the four year clinical trial.

U.S. Food and Drug Administration (FDA) has approved Afrezza Inhalation Powder for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetes.

The FDA has approved technosphere insulin, an inhaled form of human insulin, for children and adolescents aged 6 years and ...

MannKind recently received U.S. FDA approval for Afrezza Inhalation Powder for children and adolescents aged 6 and older with type 1 or type 2 diabetes, making it the first needle-free mealtime ...

New analyses examine Afrezza across pediatric A1c and efficacy, patient treatment satisfaction, use with AID algorithms and investigator-led ...

WESTLAKE VILLAGE, Calif., Jan. 06, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) announced today that its Brazilian partner, Biomm S.A., has received written notice from the Chamber of ...